Research Article
The Association between Yang-Deficient Constitution and Clinical Outcome of Highly Active Antiretroviral Therapy on People Living with HIV
Table 5
(a) Univariate analysis of Yang deficiency in HIV patients. (b) Logistic regression analysis of risk factors for mortality.
(a) |
| Variable | Category | Number/IQR | Correlation coefficient | Yang deficiency median score | value* |
| Gender | Male | 96 | N/A | 22.32 | <0.05 | Female | 46 | 32.14 | Hepatotoxicity | Yes | 4 9 | N/A | 32.14 | <0.1 | No | 93 | 25.00 | Nephrotoxicity | Yes | 11 | N/A | 37.50 | <0.1 | No | 131 | 25.00 | HIV disease staging | A | 57 | N/A | 23.21 | <0.05 | B | 16 | 34.82 | C | 69 | 25.00 | Mortality | Yes | 137 | N/A | 39.29 | <0.05 | No | 5 | 25.00 | Age | N/A | 29–41 | −0.028 | ND | 0.74 | CD4 | Annual change | 77–217 | −0.028 | ND | 0.75 | Nadir value | 19–194 | −0.053 | ND | 0.53 | CD8 | Annual change | −138–510 | −0.028 | ND | 0.74 | Nadir value | 334–737 | −0.13 | ND | 0.12 | Total number of adverse events | N/A | 1–5 | 0.16 | ND | <0.1 |
|
|
Wilcoxon rank sum test with continuity correction, Spearman’s rank correlation, and Kruskal-Wallis rank sum test were performed where appropriate.
|
(b) |
| Variable | Alive | Dead | | OR | OR 95% CI |
| Previous pneumonia | No | 99 | 1 | <0.05 | 10.42 | 1.48, 207.38 | Yes | 38 | 4 | Intestinal infections | No | 131 | 3 | <0.05 | 14.55 | 1.69, 106.00 | Yes | 6 | 2 | IRIS | No | 130 | 3 | <0.05 | 12.38 | 1.46, 87.72 | Yes | 7 | 2 | Total number of newly acquired infections after HAART | N/A | N/A | N/A | <0.05 | 1.63 | 1.20, 2.41 | Hepatotoxicity | No | 92 | 1 | <0.05 | 8.18 | 1.17, 162.48 | Yes | 45 | 4 | Nephrotoxicity | No | 129 | 2 | <0.05 | 24.19 | 3.55, 205.36 | Yes | 8 | 3 | Total number of adverse events | N/A | N/A | N/A | <0.05 | 7.85 | 1.35, 149.63 |
|
|